Advanced Non-Small Cell Lung Cancer
Conditions
Interventions
Continuning immunotherapy beyond progression:NA
Non-continuning immunotherapy beyond progression:NA
Sponsors
inling Hospital, Affiliated Hospital of Medical School, Nanjing University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically or cytologically confirmed unresectable locally advanced or metastatic NSCLC, staged according to the AJCC 8th Edition. 2. Previously received first-line treatment for advanced disease based on PD-1 or PD-L1 inhibitors, with more than 2 cycles of PD-1 or PD-L1 therapy administered. 3. Documented disease progression during or after first-line treatment for advanced disease.
Exclusion criteria
Exclusion criteria: 1. Patients who received <=2 cycles of first-line treatment with PD-1/PD-L1 inhibitors. 2. Patients with incomplete key baseline or treatment information were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival 2 (PFS-2); | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate, ORR;Disease control rate, DCR;overall survival, OS; | — |
Countries
China
Contacts
Public ContactTangfeng Lv
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University
Outcome results
None listed